PI-103 CAS: 371935-74-9
MF: C19H16N4O3
MW: 348.36
An ATP-competitive DNA-PK, PI 3-kinase, and FRAP inhibitor.

PI-103 (CAS 371935-74-9)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 114ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
PI-103 is rated 5.0 out of 5 by 1.
5
1
4
0
3
0
2
0
1
0
Nomi alternativi: PI 3-K Inhibitor V
Applicazione: PI-103 is an ATP-competitive DNA-PK, PI 3-kinase, and FRAP inhibitor
Numero CAS: 371935-74-9
Purezza: 99%
Peso molecolare: 348.36
Formula molecolare: C19H16N4O3
Solo per uso in Ricerca. Non previsto per Uso Diagnostico o Terapeutico.
* Vedere Certificato di Analisi per informazioni sul lotto specifico (incluso il contenuto d'acqua).

PI-103 is a cell-permeable pyridinylfuranopyrimidine compound that acts as an ATP-competitive inhibitor of DNA-PK, PI 3-kinase (Class IA), and FRAP (mTOR) complex 1 and 2. Studies suggest that PI-103 can induce apoptosis and an arrest in the cell cycle by inhibition of the aforementioned proteins. When PI-103 is combined with rapamycin, a prototypic mTORC1 inhibitor, synergistic suppression of AKT and ribosomal S6 protein phosphorylation are observed. In addition, PI-103 has been seen to have nominal effects inhibiting basal Na+ transport, but is very effective in abolishing insulin-induced Na+ absorption in the nephron.


Referenze

1. Demyanets, S., et al. 2010. Basic Res Cardiol. [Epub ahead of print]. PMID: 21174212
2. Mansley, M.K., et al. 2010. Br. J. Pharmacol. 161: 571-588. PMID: 20880397
3. Bagci-Onder, T., et al. 2010. Cancer Res. [Epub ahead of print]. PMID: 21084267
4. Werzowa, J., et al. 2010. J. Invest. Dermatol. [Epub ahead of print]. PMID: 21048785

Stato fisico :
Solid
Solubilità :
Soluble in DMSO (10 mg/ml), DMF (10 mg/ml), 1:2 DMSO:PBS(pH 7.2) (0.25 mg/ml), water (<1 mg/ml) at 25° C, and ethanol (<1 mg/ml) at 25° C.
CONSERVAZIONE :
Store at -20° C
Punto di scioglimento :
231.64° C (Predicted)
Punto di ebollizione :
520.25° C at 760 mmHg (Predicted)
Densità :
1.41 g/cm3 (Predicted)
Indice di rifrazione :
n20D 1.71
IC50 :
DNA-PK: IC50 = 2 nM; p110α: IC50 = 8 nM; p110β: IC50 = 88 nM; p110δ: IC50 = 48 nM; p110γ: IC50 = 150 nM; PI3-KC2β: IC50 = 26 nM; mTORC1: IC50 = 20 nM; mTORC2: IC50 = 83 nM; ATR: IC50 = 850 nM; ATM: IC50 = 920 nM; PI 3-KC2α: IC50 = ~ 1 µM; hsVPS34: IC50 = 2.3 µM
Ki Data :
Cdk5/p25: Ki= 2 µM; p33cdk2/cyclin E: Ki= 2 µM
Valori pK :
pKa: 9.06 (Predicted), pKb: 2.97 (Predicted)
Solo per uso in Ricerca. Non previsto per Uso Diagnostico o Terapeutico.
PubChem CID :
9884685
Numero MDL :
MFCD11983145
SMILES :
C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O

Download SDS (MSDS)

CERTIFICATO DI ANALISI

Adobe Acrobat Reader necessario per una visualizzazione affidabile,
stampa e commenta sui documenti PDF

PI-103 (CAS 371935-74-9)  Citazioni prodotti

Vedi quanti altri hanno usato PI-103 (CAS 371935-74-9). Clicca sulla voce per laccesso a PubMed .

Ciatazioni 1 a3 di 3 totali

PMID: # 30731136  Höllerhage, M. et al. 2019. Neuropharmacology. 149: 13-26.

PMID: # 26355082  Kwon, YC. et al. 2015. J. Virol. 89: 11549-56.

PMID: # 17804702  Fan, QW. et al. 2007. Cancer Res. 67(17): 7960-7965.

Ciatazioni 1 a3 di 3 totali
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 129ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 5ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

La Santa Cruz Biotechnology, Inc. è un leader mondiale nello sviluppo di prodotti per il mercato della ricerca biomedica. Chiamaci al numero gratuito 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. Tutti i diritti riservati. "Santa Cruz Biotechnology", ed il logo Santa Cruz Biotechnology, Inc."Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", il logo San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", ed "EZ Touch" sono marchi registrati dalla Santa Cruz Biotechnology, Inc.
Tutti i marchi sono proprietà dei rispettivi proprietari.